# A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

> **NCT06680037** · PHASE1 · RECRUITING · sponsor: **TG Therapeutics, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- B-cell Mediated Autoimmune Disorders

## Interventions

- **DRUG:** Azercabtagene zapreleucel (azer-cel)

## Key facts

- **NCT ID:** NCT06680037
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2027-12-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680037, "A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06680037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*